Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart MRI may unlock secrets of stiff heart failure

NCT ID NCT07326605

Knowledge-focused Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether special heart MRI scans can help predict serious events like death or hospital stays in people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction). Researchers will scan 3000 patients with HFpEF and 500 healthy volunteers, then follow them for 3 years. No drugs or treatments are tested—this is purely an observation study to improve how doctors assess risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2010

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with heart failure with preserved ejection fraction experienced cardiac MRI scanning

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Symptoms and/or signs of HF ≥ New York Heart Association (NYHA) class II; 2. Left ventricular ejection fraction (LVEF) of 50% or higher; 3. N-terminal fragment of the prohormone of brain natriuretic peptide (NT-proBNP) level \> 125 pg/mL or brain natriuretic peptide (BNP) level \> 35 pg/mL in sinus rhythm, or NT-proBNP level \> 365 pg/mL or BNP level \> 105 pg/mL in atrial fibrillation; 4. At least one of objective indicators of (i) cardiac structural abnormalities including LA maximum volume index (LAVi max) \> 29 mL/m2 or echocardiography-measured LV end-diastolic mass index (LVMi) ≥ 115 g/m2 for men and ≥ 95 g/m2 for women, and (ii) LV diastolic dysfunction including early and/or late diastolic mitral inflow velocity (E/A) \< 1 or early diastolic mitral inflow velocity and/or mitral annular peak early diastolic velocity (E/e') \> 13. Exclusion Criteria: 1. Primary cardiomyopathy; 2. Acute coronary syndrome; 3. Primary severe valvular heart disease; 4. Acute pulmonary embolism; 5. Severe renal dysfunction; 6. Poor image quality that was insufficient to identify myocardial endocardium and epicardium.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with preserved ejection fraction (hfpef are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with preserved ejection fraction (hfpef

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.